Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences announced a clinical trial collaboration with Amgen to evaluate IDE397, a MAT2A inhibitor, in combination with Amgen's AMG 193, targeting MTAP-null solid tumors. This partnership aims to explore the efficacy of this first-in-class synthetic lethality combination, expected to impact approximately 15% of solid tumors. Amgen will sponsor the Phase 1 trial, sharing costs with IDEAYA, while both companies retain commercial rights to their respective therapies. IDEAYA continues its ongoing Phase 1/2 trial for IDE397, evaluating it in various cancer settings.

IDEAYA Biosciences (Nasdaq: IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK. Preclinical studies show complete responses with Niraparib in various PDX and CDX HRD models, with the aim for first-in-human evaluation in H1 2023. IDEAYA is eligible for up to $960 million in total milestones from GSK, including $485 million for development and regulatory achievements, along with $475 million in commercial sales milestones. GSK will lead clinical development while covering research and development costs.

IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 11:00 AM ET. CEO Yujiro Hata will engage in a fireside chat hosted by equity research analyst Maury Raycroft. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA focuses on precision medicine in oncology, targeting specific patient populations through molecular diagnostics and synthetic lethality.

IDEAYA Biosciences (Nasdaq:IDYA) reported a strong financial position with approximately $346 million in cash and equivalents as of March 31, 2022, expected to support operations into 2025. The company is advancing several clinical trials, including the IDE397 Phase 1/2 study and updates on darovasertib combination therapies. Collaboration revenue reached $11.4 million in Q1 2022, up from $3.0 million in Q4 2021. However, net losses were $14.0 million, showing a decrease from $18.2 million the previous quarter.

IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in key investor conferences in May 2022. Scheduled events include the JP Morgan Conference on May 16, featuring a fireside chat with CEO Yujiro Hata, and the Guggenheim Synthetic Lethality Day, also on May 16, where Hata will participate in panel discussions. The Citi Biopharma Virtual Co-Panel Day is set for May 18. Interested parties can access live audio webcasts and replays on IDEAYA's website. IDEAYA specializes in synthetic lethality-focused precision medicine for targeted cancer therapeutics.

IDEAYA Biosciences (NASDAQ: IDYA) announced that the FDA has granted orphan-drug designation to darovasertib, a potential first-in-class PKC inhibitor, for treating uveal melanoma. This designation provides IDEAYA with tax credits, user fee exemptions, and seven years of marketing exclusivity post-approval. IDEAYA plans to update clinical data related to the darovasertib and crizotinib combination in mid-2022 and seeks FDA guidance for a registration-enabling trial design. Over 200 patients have been evaluated, with ongoing trials targeting additional oncology indications.

IDEAYA Biosciences has announced the appointment of Dr. Catherine Mackey to its Board of Directors. With over 30 years of experience in life sciences, Dr. Mackey previously held senior roles at Pfizer and has an extensive background in oncology research and development. Her expertise is expected to enhance IDEAYA's synthetic lethality platform and support the advancement of its drug pipeline, particularly the Phase 1 MAT2A inhibitor IDE397 and Phase 2 PKC inhibitor darovasertib. This strategic addition aims to drive progress in the company’s targeted therapeutics initiatives.

IDEAYA Biosciences (NASDAQ: IDYA) reported a strong financial position with approximately $368 million in cash as of December 31, 2021, sufficient to fund operations into 2025. The company is actively enrolling patients in Cohort 6 of the IDE397 clinical trial, revealing no serious drug-related adverse events. IDEAYA aims to expand its monotherapy and combination cohorts for IDE397 by mid-2022. Additionally, promising results from the darovasertib and crizotinib combination therapy have shown a 100% disease control rate in uveal melanoma patients, showcasing robust clinical activity and manageable side effects.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced promising interim Phase 1 clinical data for IDE397, a MAT2A inhibitor targeting solid tumors with MTAP gene deletions. The trial showed preclinical tumor SDMA suppression of 95-100% and robust plasma SAM modulation exceeding a 60% reduction. Cohort 5 reports a 95% reduction in tumor SDMA without drug-related serious adverse events. IDEAYA is expanding into monotherapy cohorts and targeting a data package delivery to GSK by mid-2022, potentially earning a $50 million option payment and up to $465 million in milestones.